Prognostic factors of lenvatinib plus pembrolizumab therapy for advanced or recurrent endometrial cancer: analysis of a multicenter cohort study in Japan
日本一项多中心队列研究分析了乐伐替尼联合帕博利珠单抗治疗晚期或复发性子宫内膜癌的预后因素。
期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-025-02842-x
Nagase, Yoshikazu; Nakagawa, Satoshi; Kobayashi, Mariya; Kurahashi, Hiroki; Ogimoto, Hiromi; Tanaka, Ayaka; Tsujie, Tomoko; Shiomi, Mayu; Otake, Akiko; Masuhara, Kanji; Yoshikawa, Kenichi; Yotsumoto, Fusanori; Kurita, Tomoko; Yoshino, Kiyoshi; Yoshioka, Emi; Egawa-Takata, Tomomi; Kudaka, Wataru; Sekine, Masayuki; Unno, Hikari; Takemura, Masahiko; Aso, Saki; Kai, Kentaro; Kobayashi, Eiji; Yokoi, Takeshi; Akada, Masashi; Kakubari, Reisa; Hisa, Tsuyoshi; Matsuzaki, Shinya; Ueda, Yutaka